On Friday, Shares of Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA), gained 2.00% to $9.18.
Ariad Pharmaceuticals, declared long-term follow-up data from the Phase 1 trial of Iclusig® (ponatinib), its approved BCR-ABL inhibitor, in heavily pretreated patients with resistant or intolerant chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia. With a median follow-up of over four years, Iclusig continues to demonstrate anti-leukemic activity in chronic-phase CML patients with limited treatment options (n=43). Overall, 72 percent of CP-CML patients achieved a major cytogenetic response on trial, 65 percent a complete cytogenetic response and 56 percent a major molecular response. Long-term safety data on ponatinib indicate that benefit-risk evaluations should guide decisions to initiate and maintain therapy, particularly in patients who may be at raised risk for arterial occlusive events.
ARIAD Pharmaceuticals, Inc., an oncology company, engages in the discovery, development, and commercialization of medicines for cancer patients. The company offers Iclusig (ponatinib), a tyrosine kinase inhibitor for the treatment of adult patients with chronic myeloid leukemia, and Philadelphia chromosome-positive acute lymphoblastic leukemia in the United States, Europe, and other territories.
Shares of salesforce.com, inc. (NYSE:CRM), inclined 0.10% to $ 72.75, during its last trading session.
salesforce.com, declared the company’s annual meeting of stockholders will be held on Thursday, Jun. 4, 2015 at 2:00 p.m. / 5:00 p.m.. The meeting will be held at Salesforce, located at 50 Fremont Street, San Francisco, California 94105. Stockholders are invited to attend the meeting and should refer to Salesforce’s proxy statement accessible at www.salesforce.com/investor for details regarding required documentation to gain admission to the meeting.
salesforce.com, inc. provides enterprise cloud computing solutions, with a focus on customer relationship administration to various businesses and industries worldwide.
At the end of Friday’s trade, Shares of Calpine Corporation (NYSE:CPN), lost -1.08% to $ 20.10.
Calpine Corporation, declared that it has closed on a $1.6 billion first lien term loan (“Term Loan”). The Term Loan, which amortizes at a rate of 1% per year, bears interest at LIBOR plus 2.75% per annum (subject to a LIBOR floor of 0.75%) and matures in 2022.
Calpine utilized the proceeds of the Term Loan to retire about $1.6 billion remaining on its 2018 first lien term loan which bore interest at a rate of LIBOR plus 3% per annum (subject to a LIBOR floor of 1%).
Calpine Corporation, a wholesale power generation company, owns and operates natural gas-fired and geothermal power plants in North America. It operates natural gas-fired combustion turbines and renewable geothermal conventional steam turbines.
Finally, Express, Inc. (NYSE:EXPR), ended its last trade with 1.32% gain, and close at $ 17.64.
Express, declared its financial results for the first quarter of 2015. These results cover the thirteen week period ended May 2, 2015.
David Kornberg, the Company’s President and Chief Executive Officer, noted that, “2015 is off to a strong start. In the first quarter, comparable sales rose by 7% and our merchandise margin expanded by 200 basis points, driving earnings above our initial expectations. Our customers responded with enthusiasm to our assortment while we intensified our inventory discipline and scaled back our promotional activity. We also continued to execute against our growth pillars and our 2015 priorities. I am particularly happy that the growth we delivered resulted from our balanced approach to running the business.”
Express, Inc. operates as a specialty apparel and accessories retailer. It offers apparel and accessories for women and men between 20 and 30 years across various aspects of lifestyles, counting work, casual, jeanswear, and going-out occasions.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
